| Diminished efficacy of programmed death-(ligand) 1 inhibition in STK11-and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status B Ricciuti, KC Arbour, JJ Lin, A Vajdi, N Vokes, L Hong, J Zhang, ... Journal of Thoracic Oncology 17 (3), 399-410, 2022 | 186 | 2022 |
| Association of high tumor mutation burden in non–small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 … B Ricciuti*, X Wang*, JV Alessi, H Rizvi, NR Mahadevan, YY Li, A Polio, ... JAMA oncology 8 (8), 1160-1168, 2022 | 143 | 2022 |
| Association between smoking history and tumor mutation burden in advanced non–small cell lung cancer X Wang, B Ricciuti, T Nguyen, X Li, MS Rabin, MM Awad, X Lin, ... Cancer research 81 (9), 2566-2573, 2021 | 88 | 2021 |
| Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer B Ricciuti, JV Alessi, A Elkrief, X Wang, A Cortellini, YY Li, VR Vaz, ... Annals of Oncology 33 (10), 1029-1040, 2022 | 39 | 2022 |
| Smoking history as a potential predictor of immune checkpoint inhibitor efficacy in metastatic non-small cell lung cancer X Wang, B Ricciuti, JV Alessi, T Nguyen, MM Awad, X Lin, BE Johnson, ... JNCI: Journal of the National Cancer Institute 113 (12), 1761-1769, 2021 | 37 | 2021 |
| Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non–Small Cell Lung Cancer B Ricciuti, J Son, JJ Okoro, A Mira, E Patrucco, Y Eum, X Wang, R Paranal, ... Clinical Cancer Research 28 (8), 1640-1650, 2022 | 29 | 2022 |
| Clinicopathologic and genomic factors impacting efficacy of first-line chemoimmunotherapy in advanced NSCLC JV Alessi*, A Elkrief*, B Ricciuti*, X Wang, A Cortellini, VR Vaz, ... Journal of Thoracic Oncology 18 (6), 731-743, 2023 | 28 | 2023 |
| Ultrasensitive detection of circulating LINE-1 ORF1p as a specific multicancer biomarker MS Taylor, C Wu, PC Fridy, SJ Zhang, Y Senussi, JC Wolters, T Cajuso, ... Cancer discovery 13 (12), 2532-2547, 2023 | 18 | 2023 |
| Prediagnosis smoking cessation and overall survival among patients with non–small cell lung cancer X Wang, CW Romero-Gutierrez, J Kothari, A Shafer, Y Li, DC Christiani JAMA network open 6 (5), e2311966-e2311966, 2023 | 10 | 2023 |
| Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC JV Alessi, B Ricciuti, X Wang, F Pecci, A Di Federico, G Lamberti, A Elkrief, ... Nature Communications 14 (1), 4238, 2023 | 7 | 2023 |
| Use of machine learning to assess the prognostic utility of radiomic features for in-hospital COVID-19 mortality Y Sun, S Salerno, X He, Z Pan, E Yang, C Sujimongkol, J Song, X Wang, ... Scientific Reports 13 (1), 7318, 2023 | 6 | 2023 |
| Impact of aneuploidy and chromosome 9p loss on tumor immune microenvironment and immune checkpoint inhibitor efficacy in non-small cell lung cancer. JV Alessi*, X Wang*, A Elkrief, B Ricciuti, YY Li, H Gupta, LF Spurr, ... Journal of Thoracic Oncology, 2023 | 5 | 2023 |
| Immune Infiltration in Tumor and Adjacent Non-Neoplastic Regions Codetermines Patient Clinical Outcomes in Early-Stage Lung Cancer C Cheng, TT Nguyen, M Tang, X Wang, C Jiang, Y Liu, I Gorlov, ... Journal of Thoracic Oncology 18 (9), 1184-1198, 2023 | 4 | 2023 |
| Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer B Ricciuti, A Elkrief, J Alessi, X Wang, Y Li, H Gupta, DM Muldoon, ... Clinical Cancer Research 29 (13), 2540-2550, 2023 | 4 | 2023 |
| Three-year outcomes and correlative analyses in patients with non–small cell lung cancer (NSCLC) and a very high PD-L1 tumor proportion score (TPS)≥ 90% treated with first … B Ricciuti, A Elkrief, JVM Alessi, X Wang, APC Barrichello, F Pecci, ... Journal of Clinical Oncology 40 (16_suppl), 9043-9043, 2022 | 4 | 2022 |
| Genomic and immunophenotypic landscape of acquired resistance to PD-(L) 1 blockade in non–small-cell lung cancer B Ricciuti, G Lamberti, SR Puchala, NR Mahadevan, JR Lin, JV Alessi, ... Journal of Clinical Oncology, JCO. 23.00580, 2024 | 2 | 2024 |
| Amplification of Wild-Type RET Represents a Novel Molecular Subtype of Several Cancer Types With Clinical Response to Selpercatinib MM Gandhi, B Ricciuti, G Harada, M Repetto, MS Gildenberg, A Singh, ... JCO Precision Oncology 7, e2300295, 2023 | 1 | 2023 |
| Advanced non-small-cell lung cancer treated with first-line pembrolizumab plus chemotherapy: Tumor response dynamics as a marker for survival M Nishino, X Wang, B Ricciuti, SC Tseng, H Park, JV Alessi, VR Vaz, ... European Radiology 33 (10), 7284-7293, 2023 | 1 | 2023 |
| Assessing the prognostic utility of clinical and radiomic features for COVID-19 patients admitted to ICU: Challenges and lessons learned Y Sun, S Salerno, Z Pan, E Yang, C Sujimongkol, J Song, X Wang, P Han, ... Harvard Data Science Review 6 (1), 2023 | 1 | 2023 |
| Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer JV Alessi, A Price, AL Richards, B Ricciuti, X Wang, A Elkrief, F Pecci, ... Journal for Immunotherapy of Cancer 11 (11), 2023 | 1 | 2023 |
Biagio RicciutiLowe Center for Thoracic Oncology, Dana-Farber Cancer InstituteVerified email at dfci.harvard.edu
